I am still sticking with my $16 share price prediction by Feb/March 2023....
Think we will get close to $10 on ROW deal, content of the deal will dictate more value....
FDA decision (95% success) will push us to the $14-$16 range I think easily....
Neu cash flow 2022-2023 is minimum $118m. not including cash from ROW upfront and royalties in any sales on Trof..
This valuation is on Trof asset alone, looming results for Phase 2 trials will potentially support/boost share price...
Hopefully no TO until we get phase 2 trial results in my view also, I feel Jon and team want to see this also...
Think this time next year $20 is also possible (12 month time)
Share Price, page-1791
-
- There are more pages in this discussion • 10,608 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.02 |
Change
0.080(0.62%) |
Mkt cap ! $1.664B | |||
| Open | High | Low | Value | Volume |
| $13.23 | $13.35 | $12.99 | $5.557M | 423.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1588 | $13.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.06 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |